MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis

Abstract

The use of risk assessment with MRI before biopsy and MRI-targeted biopsy was superior to standard transrectal ultrasonography-guided biopsy in men at clinical risk for prostate cancer who had not undergone biopsy previously. (Funded by the National Institute for Health Research and the European Association of Urology Research Foundation; PRECISION ClinicalTrials.gov number, NCT02380027 .).

Keywords

Affiliated Institutions

• University College London Hospitals NHS Foundation Trust GB
• Centre Hospitalier Universitaire de Lille FR
• Université de Lille FR
• Helsinki University Hospital FI
• University Hospital Heidelberg DE
• University Hospital of Bern CH
• Hôpital Lyon Sud FR
• Lyon College US
• Royal Free London NHS Foundation Trust GB
• Martini-Klinik DE
• Hampshire Hospitals NHS Foundation Trust GB
• Presbyterian Hospital US
• Sunnybrook Health Science Centre CA
• Hospices Civils de Lyon FR
• Erasmus MC NL
• Ghent University Hospital BE
• National Institutes of Health US
• University Medical Center US
• NIHR Birmingham Biomedical Research Centre GB
• New York Hospital Queens US
• Oulu University Hospital FI
• IRCCS Ospedale San Raffaele IT
• University of Chicago US
• NewYork–Presbyterian Hospital US
• Health Sciences Centre CA
• Jewish General Hospital CA
• Vita-Salute San Raffaele University IT
• University of Oulu FI
• Sapienza University of Rome IT
• London North West Healthcare NHS Trust GB
• NYU Langone Health US
• University of Birmingham GB
• Université de Bordeaux FR
• Hôpital Pellegrin FR
• University of Southern California US
• Whittington Health NHS Trust GB
• Cornell University US
• Radboud University Medical Center NL
• Hôpital Edouard Herriot FR
• Mayo Clinic in Arizona US
• Heidelberg University DE
• Princess Alexandra Hospital NHS Trust GB
• Essen University Hospital DE
• Radboud University Nijmegen NL

Related Publications